Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to the innovation of antibiotics and the safety of prescription drugs, over-the-counter medicines, and other consumer health care products.
Before joining Pew, Jungman was a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012 and other health- and drug-related legislation, including pandemic preparedness, drug compounding, and supply chain security measures. Previously, she was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues. Jungman serves on FDA’s Pharmacy Compounding Advisory Committee.
She has a bachelor’s degree in biology from Harvard College, a master’s in public health from Johns Hopkins University, and a Juris Doctor from Georgetown University.